Here are what G2 Intelligence considers the three most significant deals announced in the period from late August to early September.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Owlstone Medical CEO discusses recent trends, the advantages of breath testing, and the challenges that must be met for wider clinical use.
Owlstone Medical CEO Billy Boyle discusses the latest developments in breath biopsy and issues related to its wider clinical adoption.
Release of second-generation Cologuard test data and recently announced partnerships aim to position company well for the future.